CRIS Current Research Information System

PALLADINI, ARIANNA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.864
AS - Asia 3.502
EU - Europa 2.480
AF - Africa 222
SA - Sud America 154
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 1
Totale 10.230
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.792
VN - Vietnam 1.195
CN - Cina 884
SG - Singapore 766
IT - Italia 713
GB - Regno Unito 468
DE - Germania 288
HK - Hong Kong 206
SE - Svezia 200
FR - Francia 132
IN - India 122
RU - Federazione Russa 116
BR - Brasile 113
NL - Olanda 96
UA - Ucraina 89
CH - Svizzera 77
IE - Irlanda 76
CI - Costa d'Avorio 72
BD - Bangladesh 63
ZA - Sudafrica 61
JP - Giappone 59
CA - Canada 52
KR - Corea 51
FI - Finlandia 48
TG - Togo 45
EE - Estonia 35
BG - Bulgaria 32
BE - Belgio 27
PH - Filippine 22
ID - Indonesia 20
TH - Thailandia 19
AR - Argentina 18
LT - Lituania 14
JO - Giordania 13
MX - Messico 13
RO - Romania 13
AT - Austria 12
IQ - Iraq 12
PL - Polonia 12
TW - Taiwan 12
EG - Egitto 11
SC - Seychelles 10
TR - Turchia 10
PK - Pakistan 9
EC - Ecuador 8
SA - Arabia Saudita 7
AU - Australia 6
CO - Colombia 6
HR - Croazia 6
NG - Nigeria 6
CL - Cile 5
DK - Danimarca 5
MA - Marocco 5
AE - Emirati Arabi Uniti 4
ES - Italia 4
GR - Grecia 4
DO - Repubblica Dominicana 3
IR - Iran 3
LB - Libano 3
UZ - Uzbekistan 3
AZ - Azerbaigian 2
BY - Bielorussia 2
CZ - Repubblica Ceca 2
GH - Ghana 2
JM - Giamaica 2
KE - Kenya 2
KG - Kirghizistan 2
KH - Cambogia 2
KZ - Kazakistan 2
LI - Liechtenstein 2
MN - Mongolia 2
MY - Malesia 2
PS - Palestinian Territory 2
TN - Tunisia 2
VE - Venezuela 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AM - Armenia 1
AO - Angola 1
BB - Barbados 1
BJ - Benin 1
BO - Bolivia 1
DZ - Algeria 1
ET - Etiopia 1
GE - Georgia 1
HU - Ungheria 1
IL - Israele 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
MD - Moldavia 1
NI - Nicaragua 1
NZ - Nuova Zelanda 1
PE - Perù 1
PT - Portogallo 1
QA - Qatar 1
RS - Serbia 1
SI - Slovenia 1
SN - Senegal 1
ZM - Zambia 1
Totale 10.230
Salva come PNG Salva come JPEG
Città #
Singapore 538
Ashburn 441
Fairfield 392
Southend 370
Chandler 328
Ho Chi Minh City 272
Hanoi 233
Hong Kong 198
Houston 179
San Jose 177
Shanghai 174
Woodbridge 172
Wilmington 170
Bologna 161
Ann Arbor 158
Seattle 146
Dong Ket 132
Cambridge 130
Santa Clara 117
Hefei 103
Beijing 102
Princeton 93
Council Bluffs 89
Dublin 76
Boardman 74
Abidjan 72
Bern 70
Los Angeles 57
New York 57
Lauterbourg 52
Jacksonville 50
Milan 46
Lomé 45
Tokyo 44
Dallas 43
Seoul 39
Westminster 39
Bremen 37
Nanjing 37
Helsinki 36
Da Nang 35
Haiphong 35
Padova 33
Berlin 32
Sofia 32
Guangzhou 31
Buffalo 28
Jinan 28
Redmond 26
Brussels 25
Frankfurt am Main 25
Redwood City 24
São Paulo 23
Redondo Beach 21
Saint Petersburg 21
Casalecchio di Reno 20
Johannesburg 20
London 20
Tianjin 20
Turin 20
Falkenstein 19
Ottawa 19
Hải Dương 18
San Diego 18
Changsha 17
Jakarta 17
Toronto 17
Amsterdam 16
Phoenix 16
Shenyang 15
Hebei 14
Amman 13
Biên Hòa 13
Des Moines 13
Atlanta 12
Jiaxing 12
Nanchang 12
Ha Long 11
Zhengzhou 11
Bengaluru 10
Mülheim 10
Lappeenranta 9
Montreal 9
Moscow 9
Quận Bình Thạnh 9
Vienna 9
Bến Tre 8
Can Tho 8
Delhi 8
Vicenza 8
Barnet 7
Bühl 7
Bắc Giang 7
Chieti 7
Crocetta 7
Kerpen 7
Naples 7
Ningbo 7
Orem 7
Poplar 7
Totale 6.718
Salva come PNG Salva come JPEG
Nome #
IFN-γ and CD38 in Hyperprogressive Cancer Development 432
Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER-2. 386
Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft 340
Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations 324
A multi-DNA preventive vaccine for p53/Neu driven cancer syndrome 267
Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases 258
Preclinical therapy of disseminated HER-2+ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus. 253
Cancer Vaccines Co-Targeting HER2/Neu and IGF1R 247
Virus-like particle display of HER2 induces potent anti-cancer responses 232
Multiorgan Metastasis of Human HER-2+ Breast Cancer in Rag2−/−;Il2rg−/− Mice and Treatment with PI3K Inhibitor 228
Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression 219
ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1- rearranged NSCLC 216
Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy 215
Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma 211
Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model 206
Cancer immunoprevention: from mice to early clinical trials 205
Endothelin-3 production by human rhabdomyosarcoma: A possible new marker with a paracrine role. 203
HER-2/neu tolerant and non-tolerant mice for fine assessment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines 199
Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer 199
In silico modeling and in vivo efficacy of cancer preventive vaccinations 199
ImmunoGrid: Towards agent-based simulations of the human immune system at a natural scale 198
Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes 197
Lipid rafts, caveolae, and epidermal growth factor receptor family: friends or foes? 196
Evaluation of metastatic burden and recovery of human metastatic cells from a mouse model 196
The mechanisms of PD-L1 regulation in non-small-cell lung cancer (NSCLC): Which are the involved players? 193
Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice. 188
Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis 188
Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma. 187
Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis 187
High metastatic efficiency of human sarcoma cells in Rag2/gamma c double knockout mice provides a powerful test system for antimetastatic targeted therapy 187
Antimetastatic activity of a preventive cancer vaccine. 186
Human responses against HER-2-positive cancer cells in human immune system-engrafted mice. 185
HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response 180
Prevention and Therapy of Metastatic HER-2+ Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine 179
Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4. 178
Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells 177
Modeling the competition between lung metastases and the immune system using agents. 177
OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis 176
Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas 174
Activated d16HER2 Homodimers and SRC Kinase Mediate Optimal Efficacy for Trastuzumab. 169
Translational immunomics of cancer prevention. 168
Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies 164
Inhibition of prostate carcinogenesis by combined active immunoprophylaxis. 162
Expression of connective tissue growth factor (CTGF/CCN2) in a mouse model of rhabdomyosarcomagenesis. 161
HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy 152
Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system 146
Computational models as novel tools for cancer vaccines. 140
ImmunoGrid, an integrative environment for large-scale simulation of the immune system for vaccine discovery, design, and optimization 131
Mathematical and computational models in tumor immunology 127
EGFR-RAD51 gene fusion NSCLC responsiveness to different generation EGFR-TKIs: two cases and review of the literature 98
Predictive models in tumor immunology. 91
Development of cellular models expressing cynomolgus (Macaca fascicularis) HER2 for the functional evaluation of cross-reactive anti-human HER2 response 75
Targeting HGF/MET and CXCL1/CXCR2 axes bypasses resistance to KRASG12C inhibitors in NSCLC 54
Alternatives for fetal bovine serum (FBS) and sustainability of milk derivatives in cell culture 25
Requalified bovine milk as a sustainable supplement for cell cultures 22
Totale 10.453
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.215
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.215
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021263 0 0 0 0 0 0 0 0 0 0 0 263
2021/20221.005 102 47 83 38 99 70 29 54 52 66 223 142
2022/20231.261 132 154 67 183 75 99 44 66 180 54 103 104
2023/2024490 25 45 22 32 29 50 25 209 7 19 11 16
2024/20251.409 102 166 112 75 230 78 101 68 9 115 82 271
2025/20263.578 484 323 242 230 315 173 293 104 727 326 184 177
Totale 10.453